Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Glenmark Pharmaceuticals Ltd?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 001.15
1 812.45
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
What unique competitive advantages
does Glenmark Pharmaceuticals Ltd hold over its rivals?
What risks and challenges
does Glenmark Pharmaceuticals Ltd face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Glenmark Pharmaceuticals Ltd.
Provide an overview of the primary business activities
of Glenmark Pharmaceuticals Ltd.
What unique competitive advantages
does Glenmark Pharmaceuticals Ltd hold over its rivals?
What risks and challenges
does Glenmark Pharmaceuticals Ltd face in the near future?
Has there been any significant insider trading activity
in Glenmark Pharmaceuticals Ltd recently?
Summarize the latest earnings call
of Glenmark Pharmaceuticals Ltd.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Glenmark Pharmaceuticals Ltd.
Provide P/S
for Glenmark Pharmaceuticals Ltd.
Provide P/E
for Glenmark Pharmaceuticals Ltd.
Provide P/OCF
for Glenmark Pharmaceuticals Ltd.
Provide P/FCFE
for Glenmark Pharmaceuticals Ltd.
Provide P/B
for Glenmark Pharmaceuticals Ltd.
Provide EV/S
for Glenmark Pharmaceuticals Ltd.
Provide EV/GP
for Glenmark Pharmaceuticals Ltd.
Provide EV/EBITDA
for Glenmark Pharmaceuticals Ltd.
Provide EV/EBIT
for Glenmark Pharmaceuticals Ltd.
Provide EV/OCF
for Glenmark Pharmaceuticals Ltd.
Provide EV/FCFF
for Glenmark Pharmaceuticals Ltd.
Provide EV/IC
for Glenmark Pharmaceuticals Ltd.
Show me price targets
for Glenmark Pharmaceuticals Ltd made by professional analysts.
What are the Revenue projections
for Glenmark Pharmaceuticals Ltd?
How accurate were the past Revenue estimates
for Glenmark Pharmaceuticals Ltd?
What are the Net Income projections
for Glenmark Pharmaceuticals Ltd?
How accurate were the past Net Income estimates
for Glenmark Pharmaceuticals Ltd?
What are the EPS projections
for Glenmark Pharmaceuticals Ltd?
How accurate were the past EPS estimates
for Glenmark Pharmaceuticals Ltd?
What are the EBIT projections
for Glenmark Pharmaceuticals Ltd?
How accurate were the past EBIT estimates
for Glenmark Pharmaceuticals Ltd?
Compare the revenue forecasts
for Glenmark Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Glenmark Pharmaceuticals Ltd and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Glenmark Pharmaceuticals Ltd against its competitors.
Analyze the profit margins
(gross, operating, and net) of Glenmark Pharmaceuticals Ltd compared to its peers.
Compare the P/E ratios
of Glenmark Pharmaceuticals Ltd against its peers.
Discuss the investment returns and shareholder value creation
comparing Glenmark Pharmaceuticals Ltd with its peers.
Analyze the financial leverage
of Glenmark Pharmaceuticals Ltd compared to its main competitors.
Show all profitability ratios
for Glenmark Pharmaceuticals Ltd.
Provide ROE
for Glenmark Pharmaceuticals Ltd.
Provide ROA
for Glenmark Pharmaceuticals Ltd.
Provide ROIC
for Glenmark Pharmaceuticals Ltd.
Provide ROCE
for Glenmark Pharmaceuticals Ltd.
Provide Gross Margin
for Glenmark Pharmaceuticals Ltd.
Provide Operating Margin
for Glenmark Pharmaceuticals Ltd.
Provide Net Margin
for Glenmark Pharmaceuticals Ltd.
Provide FCF Margin
for Glenmark Pharmaceuticals Ltd.
Show all solvency ratios
for Glenmark Pharmaceuticals Ltd.
Provide D/E Ratio
for Glenmark Pharmaceuticals Ltd.
Provide D/A Ratio
for Glenmark Pharmaceuticals Ltd.
Provide Interest Coverage Ratio
for Glenmark Pharmaceuticals Ltd.
Provide Altman Z-Score Ratio
for Glenmark Pharmaceuticals Ltd.
Provide Quick Ratio
for Glenmark Pharmaceuticals Ltd.
Provide Current Ratio
for Glenmark Pharmaceuticals Ltd.
Provide Cash Ratio
for Glenmark Pharmaceuticals Ltd.
What is the historical Revenue growth
over the last 5 years for Glenmark Pharmaceuticals Ltd?
What is the historical Net Income growth
over the last 5 years for Glenmark Pharmaceuticals Ltd?
What is the current Free Cash Flow
of Glenmark Pharmaceuticals Ltd?
Discuss the annual earnings per share (EPS)
trend over the past five years for Glenmark Pharmaceuticals Ltd.
P/S
Price to Sales
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
Market Cap | P/S | ||||
---|---|---|---|---|---|
IN |
G
|
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
|
382.7B INR | 3.1 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
688.1B USD | 15.3 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
361B USD | 4.1 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK | 6.2 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
186.2B CHF | 3.2 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
166.9B CHF | 3.8 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
150.3B GBP | 3.6 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
199.9B USD | 3.1 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD | 70 |
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
108.4B EUR | 2.4 |
|
Revenue Growth | P/S to Growth | |||||
---|---|---|---|---|---|---|
IN |
G
|
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
|
Average P/S:
63
3.1
|
13%
|
0.2 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
15.3
|
23%
|
0.7 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
578.3
|
9%
|
64.3 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
4.1
|
3%
|
1.4 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
6.2
|
17%
|
0.4 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
3.2
|
5%
|
0.6 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
3.8
|
3%
|
1.3 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
3.6
|
7%
|
0.5 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
3.1
|
5%
|
0.6 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
70
|
N/A | N/A |
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
2.4
|
6%
|
0.4 |
|
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.